[
  {
    "ts": null,
    "headline": "RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?",
    "summary": "Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.",
    "url": "https://finnhub.io/api/news?id=f12b7714d439ea56b0fc3578799d56f7a9ab224292d5cb68f7d97af2372a6326",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756146180,
      "headline": "RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?",
      "id": 136522377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.",
      "url": "https://finnhub.io/api/news?id=f12b7714d439ea56b0fc3578799d56f7a9ab224292d5cb68f7d97af2372a6326"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=e32ed23490e8099dd1e239d73af9e23190aaa571c48d7a895aa3f32a9ca29ce5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756139460,
      "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "id": 136541730,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=e32ed23490e8099dd1e239d73af9e23190aaa571c48d7a895aa3f32a9ca29ce5"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference",
    "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer will take part in a fireside chat at 9:15 a.m., Eastern time.",
    "url": "https://finnhub.io/api/news?id=0b614b2a00d287245d0439f6f54778062681432c48c567531ae62ddf7258f1a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756126800,
      "headline": "Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference",
      "id": 136507902,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer will take part in a fireside chat at 9:15 a.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=0b614b2a00d287245d0439f6f54778062681432c48c567531ae62ddf7258f1a2"
    }
  },
  {
    "ts": null,
    "headline": "Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib",
    "summary": "- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports",
    "url": "https://finnhub.io/api/news?id=f10d74942a2499fcbfcdebd4a95b8253bb4a013b302c11f07a3b6ea7320959f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756123200,
      "headline": "Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib",
      "id": 136507904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports",
      "url": "https://finnhub.io/api/news?id=f10d74942a2499fcbfcdebd4a95b8253bb4a013b302c11f07a3b6ea7320959f6"
    }
  },
  {
    "ts": null,
    "headline": "Immuneering Shares Climb On Supply Agreement with Eli Lilly",
    "summary": "Immuneering Shares Climb On Supply Agreement with Eli Lilly",
    "url": "https://finnhub.io/api/news?id=e14721313f30525ff5c0d794acf78736398bfe35cfb9bbd5c7ad98e094226625",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756122240,
      "headline": "Immuneering Shares Climb On Supply Agreement with Eli Lilly",
      "id": 136541731,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Immuneering Shares Climb On Supply Agreement with Eli Lilly",
      "url": "https://finnhub.io/api/news?id=e14721313f30525ff5c0d794acf78736398bfe35cfb9bbd5c7ad98e094226625"
    }
  },
  {
    "ts": null,
    "headline": "Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors",
    "summary": "Financing will enable the completion of the ongoing Phase 1/2 clinical trial of INX-315 in patients with recurrent advanced/metastatic cancerRESEARCH TRIANGLE PARK, N.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced it has secured a $11.25 million extension to its Series B financing. The Series B extension invest",
    "url": "https://finnhub.io/api/news?id=4ea93bc455467ada5e2fb040694a7f0ee794072dd13571440b6c9d859625bba5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756119600,
      "headline": "Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors",
      "id": 136507905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Financing will enable the completion of the ongoing Phase 1/2 clinical trial of INX-315 in patients with recurrent advanced/metastatic cancerRESEARCH TRIANGLE PARK, N.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced it has secured a $11.25 million extension to its Series B financing. The Series B extension invest",
      "url": "https://finnhub.io/api/news?id=4ea93bc455467ada5e2fb040694a7f0ee794072dd13571440b6c9d859625bba5"
    }
  },
  {
    "ts": null,
    "headline": "Stocks slip on Wall Street after last week's rally",
    "summary": "Stocks on Wall Street closed broadly lower Monday, giving back some of the big gains the market notched last week on hopes for interest rate cuts from the Federal Reserve.  The Nasdaq composite closed 0.2% lower.  Gains for several big technology stocks helped temper the market’s losses.",
    "url": "https://finnhub.io/api/news?id=fade8cd05123e2a52052d29ef95836709becf227b6bec44edbff90a33cf39a88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756099360,
      "headline": "Stocks slip on Wall Street after last week's rally",
      "id": 136522378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stocks on Wall Street closed broadly lower Monday, giving back some of the big gains the market notched last week on hopes for interest rate cuts from the Federal Reserve.  The Nasdaq composite closed 0.2% lower.  Gains for several big technology stocks helped temper the market’s losses.",
      "url": "https://finnhub.io/api/news?id=fade8cd05123e2a52052d29ef95836709becf227b6bec44edbff90a33cf39a88"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Launches Easy Mounjaro Pen in India Amid Growing Diabetes Market",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company (NYSE:LLY) launched the easy-to-use injector pen of its weight-loss and diabetes drug, Mounjaro in India on August 13. The launch comes two months after its rival Novo Nordisk released its weight loss drug Wegovy […]",
    "url": "https://finnhub.io/api/news?id=d86920f2a7622f57c21ece246e13ecd6a2561cf2e57e5336ffcf6136ea461521",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756094883,
      "headline": "Eli Lilly (LLY) Launches Easy Mounjaro Pen in India Amid Growing Diabetes Market",
      "id": 136507906,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company (NYSE:LLY) launched the easy-to-use injector pen of its weight-loss and diabetes drug, Mounjaro in India on August 13. The launch comes two months after its rival Novo Nordisk released its weight loss drug Wegovy […]",
      "url": "https://finnhub.io/api/news?id=d86920f2a7622f57c21ece246e13ecd6a2561cf2e57e5336ffcf6136ea461521"
    }
  }
]